Changing how obesity is understood and treated

Approximately 42% of adults in the U.S. are affected by obesity, putting them at increased risk for heart disease, stroke, Type 2 diabetes, cancer, knee and hip disease, and premature death. In fact, obesity drives $480B of direct healthcare costs annually in the U.S., in large part because existing “one size fits all” therapies have proven ineffective for roughly 70% of patients suffering from obesity.

That’s why Health2047 launched Phenomix Sciences: To address long-standing physician challenges in the diagnosis and treatment of obesity. 

Founded by physician-scientists Andres Acosta, M.D., Ph.D., and Michael Camilleri, M.D. at Mayo Clinic, and led by CEO Mark Bagnall, former Executive in Residence at Health2047, Phenomix offers physicians a solution to distinguish between four types of obesity early in a patient’s care. The company’s MyPhenomeTM test uses phenotype-driven multi-omics technology that—together with rigorous analysis of clinical data using sophisticated AI tools—requires only a single sample to determine the appropriate phenotype.

Obesity is not a single disease

Rather, it is a constellation of diseases that can be grouped into four primary phenotypes:

  1. Hungry Brain®: defect of satiation (the brain not knowing when to stop eating)
  2. Hungry Gut®: defect of satiety (eating in between meals to satisfy hunger)
  3. Emotional Hunger®: emotional reward from eating (eating in response to negative or positive emotions
  4. Slow Burn®: defect in energy expenditure (slow basal metabolic rate and low overall activity level)

Phenomix’s precision medicine approach addresses long-standing physician pain points including the well documented but poorly understood variability in response to treatment. The company’s MyPhenomeTM test gives doctors the ability to prescribe individualized anti-obesity therapies that are more effective.

For more information on Phenomix Sciences, visit www.phenomixsciences.com.